title: A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits.
abstract: The military population has a high disease burden of acute viral respiratory infections in China. To assess the efficacy and safety of a low-dose recombinant human interferon alpha-2b (rIFNalpha-2b) nasal spray in preventing acute viral respiratory infections in military population, we performed this randomized controlled trial. The results showed that application of the rIFNalpha-2b nasal spray had the benefits in prevention of infections caused by influenza A virus, influenza B virus parainfluenza viruses 1-3 and adenovirus species B. However, no benefit was seen in preventing respiratory syncytial virus. No severe adverse events were reported. Therefore, the rIFNalpha-2b nasal spray was effective and well tolerated for preventing common viral respiratory infections in the military recruits.
authors.affiliation: Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, 1838 Guangzhou North Road, Guangzhou, 510515 Guangdong Province, China.
authors.forename: Lulu
authors.initials: L
authors.lastname: Gao
authors.forename: Shouyi
authors.initials: S
authors.lastname: Yu
authors.forename: Qing
authors.initials: Q
authors.lastname: Chen
authors.forename: Zhaojun
authors.initials: Z
authors.lastname: Duan
authors.forename: Jie
authors.initials: J
authors.lastname: Zhou
authors.forename: Chen
authors.initials: C
authors.lastname: Mao
authors.forename: Dexian
authors.initials: D
authors.lastname: Yu
authors.forename: Wenchang
authors.initials: W
authors.lastname: Zhu
authors.forename: Jun
authors.initials: J
authors.lastname: Nie
authors.forename: Yunde
authors.initials: Y
authors.lastname: Hou
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002681:China; D004311:Double-Blind Method; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008889:Military Personnel; D011994:Recombinant Proteins; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000517:prevention & control* / Q000821:virology; D014777:Virus Diseases / Q000188:drug therapy / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D007075:Immunoglobulin M; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
references.citation: Antiviral Res. 2002 Aug;55(2):227-78
references.pmid: 12103428
references.citation: Vaccine. 2002 Dec 20;20 Suppl 5:B36-9
references.pmid: 12477417
references.citation: Vaccine. 2005 Mar 14;23(16):1981-5
references.pmid: 15734071
references.citation: Emerg Infect Dis. 2006 Jan;12(1):29-33
references.pmid: 16494713
references.citation: J Clin Virol. 2008 Sep;43(1):120-2
references.pmid: 18538629
references.citation: Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2003 Sep;17(3):205-8
references.pmid: 15340558
references.citation: J Clin Epidemiol. 2003 Dec;56(12):1218-23
references.pmid: 14680673
references.citation: Mil Med. 2005 Jan;170(1):94-7
references.pmid: 15724862
references.citation: Chest. 2003 Jan;123(1):209-16
references.pmid: 12527624
references.citation: Arch Dis Child. 1993 Oct;69(4):440-2
references.pmid: 8259875
references.citation: Antiviral Res. 1990 Jul;14(1):3-10
references.pmid: 2080867
references.citation: Vaccine. 2007 Oct 10;25(41):7017-30
references.pmid: 17728025
references.citation: J Infect Dis. 1986 Jul;154(1):128-33
references.pmid: 3011917
references.citation: J Infect Dis. 1984 Aug;150(2):181-8
references.pmid: 6381611
references.citation: Clin Infect Dis. 2002 Oct 1;35(7):808-18
references.pmid: 12228817
references.citation: J Infect Dis. 1986 Sep;154(3):443-7
references.pmid: 3016111
references.citation: Emerg Infect Dis. 2006 Jan;12(1):23-8
references.pmid: 16494712
references.citation: Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):207-10
references.pmid: 16261198
references.citation: Antiviral Res. 2006 Jun;70(2):1-16
references.pmid: 16513187
references.citation: Vaccine. 2008 Jun 2;26(23):2890-8
references.pmid: 18448211
references.citation: J Med Virol. 1985 Oct;17(2):99-106
references.pmid: 2997387
references.citation: J Infect Dis. 1983 Nov;148(5):914-21
references.pmid: 6355321
references.citation: Med J Aust. 1990 May 21;152(10):524, 527-8
references.pmid: 1692602
references.citation: Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):211-5
references.pmid: 16261199
references.citation: J Infect Dis. 2004 Apr 1;189(7):1164-7
references.pmid: 15031783